H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Rate of Smoking AbstinencePrimary· 18 months & 24 months post study enrollment
Percentage rate of smoking abstinence for participants who received If You Vape booklets, compared to: A) participants in an assessment-only condition; B) participants in a generic self-help condition comprising existing smoking cessation booklets.
Group
Value
95% CI
ASSESS at 18 Months
33
ASSESS at 24 Months
40
GENERIC at 18 Months
37
GENERIC at 24 Months
42
eTARGET at 18 Months
38
eTARGET at 24 Months
42
Changes in the Use of Tobacco ProductsSecondary· 18 and 24 months post study enrollment
As a surveillance study, investigators will track changes in the use of both tobacco cigarettes and e-cigarettes over time for ASSESS group only
Group
Value
95% CI
Asses Cigarette Use at 18 Months
33
ASSESS Cigarette Use at 24 Months
40
ASSES Vaping at 18 Months
27
ASSESS Vaping at 24 Months
32
Study 2: Cost EffectivenessSecondary· 18 months and 24 months after study recruitment
Cost per incremental cessation will be measured using USD spent on the self help materials provided to the participants in the Generic and eTarget groups at 18 months and 24 months. \*\*\*Total cost was calculated for the intervention and not calculated as per participant cost
Group
Value
95% CI
ASSESS Group at 18 Months
0
ASSESS Group at 24 Months
0
GENERIC Group at 18 Months
1535
GENERIC Group at 24 Months
2369
eTARGET Group at 18 Months
1000
eTarget Group at 24 Months
2253
Sponsor's own description
The purpose of this study is to develop and test a series of booklets designed to assist smokers of tobacco cigarettes who are also using e-cigarettes (dual users) in quitting smoking and remaining smoke-free.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 23 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02416011.